NCT04952064View on ClinicalTrials.gov

An Exploratory Study of Ganglioside GM1 in Acute Ischemic Stroke

PHASE4CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

July 28, 2021

Primary Completion Date

July 18, 2022

Study Completion Date

July 18, 2022

Conditions
Stroke, Ischemic
Interventions
DRUG

Monosialoganglioside GM1

Monosialoganglioside GM1 diluted with 0.9% normal saline 100ml, iv, daily for 12-14 days

Trial Locations (1)

Unknown

General Hospital of ShenYang Military Region, Shenyang

All Listed Sponsors
collaborator

The Third Xiangya Hospital of Central South University

OTHER

lead

General Hospital of Shenyang Military Region

OTHER

NCT04952064 - An Exploratory Study of Ganglioside GM1 in Acute Ischemic Stroke | Biotech Hunter | Biotech Hunter